Lessig, L., Republic, Lost: How Money Corrupts Congress – and a Plan to Stop It (New York: Twelve, 2011); Thompson, D. F., Ethics in Congress: From Individual to Institutional Corruption (Washington, D.C.: The Brookings Institution, 1995); Thompson, D. F., “Two Concepts of Corruption: Making Campaigns Safe for Democracy,” George Washington Law Review 73, no. 5 & 6 (2005): 1036–1069. For other work related to institutional corruption, see the web page of the Lab at the Safra, Edmond J. Center for Ethics, which has links to working papers, blogs, and information about research of Lab Fellows: <http://www.ethics.harvard.edu/lab> (last visited July 29, 2013).Google Scholar

Jorgensen, P. D., “Pharmaceuticals, Political Money, and Public Policy: A Theoretical and Empirical Agenda,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 553–555.CrossRefGoogle Scholar

Gagnon, M.-A., “Corruption of Pharmaceutical Markets: Addressing the Misalignment of Financial Incentives and Public Health,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 571–580.CrossRefGoogle Scholar

Rodwin, M. A., “Five Un-Easy Pieces to Pharmaceutical Policy Reform,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 581–589.CrossRefGoogle Scholar

Light, D. W. Lexchin, J. Darrow, J. J., “Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 590–600.CrossRefGoogle Scholar

Miller, J. E., “From Bad Pharma to Good Pharma: Aligning Market Forces with Good and Trustworthy Practices through Accreditation, Certification, & Rating,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 601–610.CrossRefGoogle Scholar

Brown, A., “Understanding Pharmaceutical Research Manipulation in the Context of Accounting Manipulation,” Journal of Law, Medicine, & Ethics 41, no. 3 (2013): 611–619.CrossRefGoogle Scholar

Feldman, Y. Gauthier, R. Schuler, T., “Curbing Misconduct in the Pharmaceutical Industry: Insights from Behavioral Ethics and the Behavioral Approach to Law,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 620–628.CrossRefGoogle Scholar

Gray, G. C., “The Ethics of Pharmaceutical Research Funding: A Social Organization Approach,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 629–634.CrossRefGoogle Scholar

Sismondo, S., “Key Opinion Leaders and the Corruption of Medical Knowledge: What the Sunshine Act Will and Won't Cast Light On,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 635–643.CrossRefGoogle Scholar

Cosgrove, L. Wheeler, E., “Drug Firms, Codification of Diagnostic Categories and Bias in Clinical Guidelines,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 644–653.CrossRefGoogle Scholar

Kassirer, J., On the Take: How Medicine's Complicity with Big Business Can Endanger Your Health (Oxford University Press, 2005).CrossRefGoogle Scholar

Rodwin, M. A., “Rooting Out Institutional Corruption to Manage Inappropriate Off-Label Drug Use,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 654–664.CrossRefGoogle Scholar

Sah, S. Fugh-Berman, A., “Physicians under the Influence: Social Psychology and Industry Marketing Strategies,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 665–672.CrossRefGoogle Scholar

Landa, A. S. Elliott, C., “From Community to Commodity: The Ethics of Pharma-Funded Social Networking Sites for Physicians,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 673–679.CrossRefGoogle Scholar

Rodwin, M. A., “Patient Accountability and Quality of Care: Lessons from Medical Consumerism and the Patients' Rights, Women's Health and Disability Rights Movements,” American Journal of Law and Medicine 20, nos. 1 & 2 (1994): 147–167; Rodwin, M. A., “Exit and Voice in American Health Care,” Michigan Journal of Law Reform 32, no. 4 (1999): 1041–1067.Google Scholar

Rose, S. L., “Patient Advocacy Organizations: Institutional Conflicts of Interest, Trust, and Trustworthiness,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 680–687.CrossRefGoogle Scholar

Jorgensen, P. D., “Pharmaceuticals, Political Money, and Public Policy: A Theoretical and Empirical Agenda,” Journal of Law, Medicine & Ethics 14, no. 3 (2013): 561–570.CrossRefGoogle Scholar

See Light, Lexchin, Darrow, , supra note 5.Google Scholar

See Rodwin, , supra note 4.Google Scholar

See Sismondo, , supra note 10.Google Scholar

See Brown, , supra note 7.Google Scholar

See Gray, , supra note 9.Google Scholar

See Cosgrove, Wheeler, , supra note 11.Google Scholar

See Sah, Fugh-Berman, , supra note 14.Google Scholar

See Landa, Elliott, , supra note 15.Google Scholar

See Rose, , supra note 17.Google Scholar

See Light, Lexchin, Darrow, , supra note 5; Gagnon, , supra note 3; Rodwin, , supra note 4.Google Scholar

See Rodwin, , supra note 13.Google Scholar

See Brown, , supra note 7.Google Scholar

See Feldman, Gauthier, Schuler, , supra note 8.Google Scholar

See Miller, , supra note 6.Google Scholar

See Sah, Fugh-Berman, , supra note 14.Google Scholar

See Sismondo, , supra note 10.Google Scholar

See Rodwin, , supra note 13.Google Scholar

See Landa, Elliott, , supra note 15.Google Scholar

See Gagnon, , supra note 3.Google Scholar

See Light, Lexchin, Darrow, , supra note 5Google Scholar

Rodwin, M. A., “Conflicts of Interest: The Limitations of Disclosure,” New England Journal of Medicine 321, no. 20 (1989): 1405–1408. See also, Rodwin, M. A., Medicine, Money and Morals: Physicians' Conflicts of Interest (New York: Oxford University Press, 1993): at 213–219; Rodwin, M. A., Conflicts of Interest and the Future of Medicine: The United States, France and Japan (New York: Oxford University Press, 2011): at 214–219.Google Scholar

See Sismondo, , supra note 10.Google Scholar

See Cosgrove, Wheeler, , supra note 11.Google Scholar

See Feldman, Gauthier, Schuler, , supra note 8.Google Scholar

See Rose, , supra note 17.Google Scholar